dMMR
About
Biomarker Type: Mismatch Repair
Present: True
Status: Deficient
Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | PD-L1 >= 50%, Wild type ALK, Wild type EGFR, dMMR | Non-Small Cell Lung Cancer | Cemiplimab | |
| FDA (1) | dMMR | Endometrial Carcinoma | Carboplatin, Dostarlimab, Paclitaxel | |
| FDA (1) HC (1) | dMMR | Endometrial Carcinoma | Dostarlimab | |
| FDA (1) | dMMR | Any solid tumor | Dostarlimab | |
| FDA (1) HC (1) | dMMR | Endometrial Carcinoma | Carboplatin, Durvalumab, Paclitaxel | |
| FDA (1) HC (1) | dMMR | Any solid tumor | Pembrolizumab | |
| FDA (1) HC (1) | dMMR | Colorectal Adenocarcinoma | Pembrolizumab | |
| FDA (2) | dMMR | Colorectal Adenocarcinoma | Ipilimumab, Nivolumab | |
| FDA (1) | dMMR | Colorectal Adenocarcinoma | Nivolumab |